Fifty years chlorpromazine: a historical perspective - PubMed (original) (raw)
Fifty years chlorpromazine: a historical perspective
Thomas A Ban. Neuropsychiatr Dis Treat. 2007 Aug.
Abstract
Chlorpromazine was synthesized in December 1951 in the laboratories of Rhône-Poiulenc, and became available on prescription in France in November 1952. Its effectiveness was reflected in the transformation of disturbed wards; its commercial success stimulated the development of other psychotropic drugs. Recognition of chemical mediation at the site of the synapse, followed by the introduction of the spectrophotofluorimeter first, and receptor assays subsequently, led to the demonstration that chlorpromazine blocks dopamine receptors. Treatment with chlorpromazine focused attention on the heterogeneity of schizophrenia in terms of responsiveness to treatment. By the mid-1980s there was sufficient evidence to believe that resolving this heterogeneity is a prerequisite for developing more effective treatments. Chlorpromazine was instrumental in the development of neuropsychopharmacology, a new discipline dedicated to the study of mental pathology with the employment of centrally acting drugs.
Keywords: chlorpromazine; history; neuropsychopharmacology; pharmacotherapy; psychiatry; schizophrenia.
Similar articles
- History of the discovery and clinical introduction of chlorpromazine.
López-Muñoz F, Alamo C, Cuenca E, Shen WW, Clervoy P, Rubio G. López-Muñoz F, et al. Ann Clin Psychiatry. 2005 Jul-Sep;17(3):113-35. doi: 10.1080/10401230591002002. Ann Clin Psychiatry. 2005. PMID: 16433053 - Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
Yıldız M, Osman E. Yıldız M, et al. Turk Psikiyatri Derg. 2022 Summer;33(2):146-148. doi: 10.5080/u26315. Turk Psikiyatri Derg. 2022. PMID: 35730516 English, Turkish. - Pharmacotherapy of mental illness--a historical analysis.
Ban TA. Ban TA. Prog Neuropsychopharmacol Biol Psychiatry. 2001 May;25(4):709-27. doi: 10.1016/s0278-5846(01)00160-9. Prog Neuropsychopharmacol Biol Psychiatry. 2001. PMID: 11383974 Review. - Towards a clinical methodology for neuropsychopharmacological research.
Ban TA. Ban TA. Neuropsychopharmacol Hung. 2007 Jun;9(2):81-90. Neuropsychopharmacol Hung. 2007. PMID: 17970531 Review. - The chlorpromazine enigma.
Baumeister AA. Baumeister AA. J Hist Neurosci. 2013;22(1):14-29. doi: 10.1080/0964704X.2012.664087. J Hist Neurosci. 2013. PMID: 23323529
Cited by
- Mental health outcomes before psychotropic medications: a retrospective case series of one state hospital records from 1945 to 1954.
Chapleau A, Harrison J, Love S, Sherman D. Chapleau A, et al. BMC Health Serv Res. 2023 Mar 15;23(1):257. doi: 10.1186/s12913-023-09235-8. BMC Health Serv Res. 2023. PMID: 36922840 Free PMC article. - Civil Commitment Law with a Focus on Hospitalized Patients History and Practice in Kansas: Part I and Part II.
Masolak DD, Parker P, Lincoln J. Masolak DD, et al. Kans J Med. 2023 Jan 18;16:21-24. doi: 10.17161/kjm.vol16.18707. eCollection 2023. Kans J Med. 2023. PMID: 36703946 Free PMC article. No abstract available. - Refocusing the Use of Psychiatric Drugs for Treatment of Gastrointestinal Cancers.
Avendaño-Félix M, Aguilar-Medina M, Bermudez M, Lizárraga-Verdugo E, López-Camarillo C, Ramos-Payán R. Avendaño-Félix M, et al. Front Oncol. 2020 Aug 14;10:1452. doi: 10.3389/fonc.2020.01452. eCollection 2020. Front Oncol. 2020. PMID: 32923398 Free PMC article. Review. - New Paradigms of Old Psychedelics in Schizophrenia.
Mahmood D, Alenezi SK, Anwar MJ, Azam F, Qureshi KA, Jaremko M. Mahmood D, et al. Pharmaceuticals (Basel). 2022 May 23;15(5):640. doi: 10.3390/ph15050640. Pharmaceuticals (Basel). 2022. PMID: 35631466 Free PMC article. Review. - Five-year trend of antipsychotic prescription practices in a district Hospital in Ghana: A retrospective study.
Daliri DB, Afaya A, Laari TT, Fredrick A, Ankamah AG, Annan S, Abagye N. Daliri DB, et al. Neuropsychopharmacol Rep. 2023 Sep;43(3):434-439. doi: 10.1002/npr2.12372. Epub 2023 Aug 13. Neuropsychopharmacol Rep. 2023. PMID: 37574802 Free PMC article.
References
- Anton-Stephens D. Preliminary observations on the psychiatric uses of chlorpromazine (Largactil) Journal of Mental Science. 1954;100:543–57. - PubMed
- Arnold OH, Hilt S, Solma W. Über die Anwendung eines vegatativen Hemmungs stoffes in der psychiatrischen Therapie. Wiener Medizinische Wochenschrift. 1952;102:965–9. - PubMed
- Ayd FJ. A clinical analysis of the differential effects of phenothiazine derivatives. In: Bradley PB, Deniker P, Radouco-Thomas C, editors. Neuropsychopharmacology . Amsterdam: Elsevier; 1959. pp. 487–8.
- Ban TA. Psychopharmacology. Baltimore: Williams & Wilkins; 1969. p. 431.
- Ban TA. Schizophrenia: A Psychopharmacological Approach. Springfield: Charles C. Thomas; 1972. pp. 68–70.
LinkOut - more resources
Full Text Sources